Rodriguez-Peralvarez, ManuelColmenero, JordiSalcedo, Magdalena2023-02-092023-02-092021-04-03Rodríguez-Perálvarez M, Colmenero J, Salcedo M; Spanish Society of Liver Transplantation (SETH). Reply to: "Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients". J Hepatol. 2021 Jul;75(1):228-229http://hdl.handle.net/10668/17590We read with great interest the letter by G. J. Webb et al. regarding our recent nationwide study promoted by the Spanish Society of Liver Transplantation (SETH), which evaluated the incidence and outcomes of coronavirus disease 2019 (COVID-19) in liver transplant (LT) patients.2 The authors merged the SETH data with their own international cohort (COVID-Hep/SECURE-Cirrhosis)3 resulting in 258 LT patients with COVID-19. The combined data analysis allowed them to highlight the importance of age and comorbidities as key factors influencing outcomes. We completely agree with this conclusion, which may also be true for non-transplant patients with COVID19. However, some statements require further clarification.enCOVID-19SARS-CoV-2Calcineurin inhibitorsEverolimusImmunosuppressionMycophenolatePneumoniaTacrolimusTransplantationCOVID-19Calcineurin inhibitorsComorbidityHumansImmunosuppressive agentsLiver transplantationSARS-CoV-2research article33862040open accessComorbilidadInhibidores de la calcineurinaInmunosupresoresTrasplante de hígado10.1016/j.jhep.2021.04.0051600-0641PMC8056821http://www.journal-of-hepatology.eu/article/S0168827821002397/pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056821/pdf